UCP1 -3826 AG+GG Genotypes, Adiponectin, and Leptin/adiponectin Ratio in Severe Obesity

Overview

Journal J Endocrinol Invest

Publisher Springer

Specialty Endocrinology

Date 2009 May 29

PMID 19474520

Citations 13

Authors

G Labruna

F Pasanisi

C Nardelli

G Tarantino

D F Vitale

R Bracale

C Finelli

M P Genua

F Contaldo

L Sacchetti

Affiliations

Soon will be listed here.

Abstract

Background And Aims: Non-alcoholic fatty liver disease (NAFLD) and metabolic syndrome (MS) are well-recognized complications of obesity. This study was designed to evaluate the role of the UCP1 -3826 A>G polymorphism, adiponectin levels, leptin/adiponectin ratio (L/A), and main biochemical parameters in 102 unrelated severely obese adults [61 females and 41 males, median body mass index (BMI) = 47.8 kg/m2] with NAFLD, with (MS+) or without MS (MS-) from Southern Italy.

Subject And Methods: The UCP1 polymorphism was tested by the TaqMan method, main biochemical parameters by routinary methods, adiponectin, and leptin serum levels by enzyme-linked immunosorbent assay. MS was diagnosed according to the American Heart Association criteria, liver steatosis was detected by ultrasound.

Results: MS was present in 53% male and 66% female obese patients. Only total cholesterol (p=0.04 males and p=0.002 females) and L/A ratio (p=0.03 males) differed between MS+ and MS- obese patients. At multivariate analysis, severe liver steatosis was significantly associated with: UCP1 (AG+GG) genotypes [odds ratio-confidence interval (OR-CI): 4.25; 1.12-16.13], MS (OR-CI: 8.47; 1.78-40.25), low adiponectin levels (OR-CI: 0.92; 0.87-0.98), high alanine aminotransferase levels (OR-CI: 1.03; 1.00-1.06), age (ORCI: 1.08; 1.00-1.15), and male gender (OR-CI: 10.78; 1.61- 71.96).

Conclusion: In addition to traditional factors, total cholesterol and L/A ratio appear to contribute to MS characterization in severe obesity. Furthermore, the UCP1 (AG+GG) genotypes and low adiponectin levels could predispose to a more severe liver steatosis independently of MS presence. Based on our data, polymorphic UCP1 (AG+GG) obese patients with low adiponectin levels appear to be high-risk subjects for worsening of liver steatosis, a NAFLD, possibly requiring a second-step evaluation by liver biopsy.

Citing Articles

Phosphorylation: new star of pathogenesis and treatment in steatotic liver disease.

Lv T, Lou Y, Yan Q, Nie L, Cheng Z, Zhou X Lipids Health Dis. 2024; 23(1):50.

PMID: 38368351 PMC: 10873984. DOI: 10.1186/s12944-024-02037-9.

Loss of Uncoupling Protein 1 Expression in the Subcutaneous Adipose Tissue Predicts Childhood Obesity.

Gyurina K, Yarmak M, Sasi-Szabo L, Molnar S, Mehes G, Roszer T Int J Mol Sci. 2023; 24(23).

PMID: 38069028 PMC: 10706300. DOI: 10.3390/ijms242316706.

Prevalence of uncoupling protein one genetic polymorphisms and their relationship with cardiovascular and metabolic health.

Dinas P, Nintou E, Vliora M, Pravednikova A, Sakellariou P, Witkowicz A PLoS One. 2022; 17(4):e0266386.

PMID: 35482655 PMC: 9049362. DOI: 10.1371/journal.pone.0266386.

Adiponectin: An Indicator for Metabolic Syndrome.

Yosaee S, Khodadost M, Esteghamati A, Speakman J, Djafarian K, Bitarafan V Iran J Public Health. 2019; 48(6):1106-1115.

PMID: 31341853 PMC: 6635323.

NAFLD/NASH in patients with type 2 diabetes and related treatment options.

Radaelli M, Martucci F, Perra S, Accornero S, Castoldi G, Lattuada G J Endocrinol Invest. 2017; 41(5):509-521.

PMID: 29189999 DOI: 10.1007/s40618-017-0799-3.

References

Ikejima K, Okumura K, Kon K, Takei Y, Sato N . Role of adipocytokines in hepatic fibrogenesis. J Gastroenterol Hepatol. 2007; 22 Suppl 1:S87-92. DOI: 10.1111/j.1440-1746.2007.04961.x. View

Caballero B . The global epidemic of obesity: an overview. Epidemiol Rev. 2007; 29:1-5. DOI: 10.1093/epirev/mxm012. View

Kontani Y, Wang Y, Kimura K, Inokuma K, Saito M, Suzuki-Miura T . UCP1 deficiency increases susceptibility to diet-induced obesity with age. Aging Cell. 2005; 4(3):147-55. DOI: 10.1111/j.1474-9726.2005.00157.x. View

Scheen A, Luyckx F . Obesity and liver disease. Best Pract Res Clin Endocrinol Metab. 2002; 16(4):703-16. DOI: 10.1053/beem.2002.0225. View

Marchesini G, Melchionda N, Apolone G, Cuzzolaro M, Mannucci E, Corica F . The metabolic syndrome in treatment-seeking obese persons. Metabolism. 2004; 53(4):435-40. DOI: 10.1016/j.metabol.2003.10.026. View

Fantuzzi G . Adipose tissue, adipokines, and inflammation. J Allergy Clin Immunol. 2005; 115(5):911-9. DOI: 10.1016/j.jaci.2005.02.023. View

Yang W, Kelly T, He J . Genetic epidemiology of obesity. Epidemiol Rev. 2007; 29:49-61. DOI: 10.1093/epirev/mxm004. View

Kiec-Wilk B, Wybranska I, Malczewska-Malec M, Partyka L, Niedbal S, Jabrocka A . Correlation of the -3826A >G polymorphism in the promoter of the uncoupling protein 1 gene with obesity and metabolic disorders in obese families from southern Poland. J Physiol Pharmacol. 2002; 53(3):477-90. View

Mozo J, Emre Y, Bouillaud F, Ricquier D, Criscuolo F . Thermoregulation: what role for UCPs in mammals and birds?. Biosci Rep. 2005; 25(3-4):227-49. DOI: 10.1007/s10540-005-2887-4. View

10.

Cinti S . The role of brown adipose tissue in human obesity. Nutr Metab Cardiovasc Dis. 2006; 16(8):569-74. DOI: 10.1016/j.numecd.2006.07.009. View

11.

Urhammer S, Hansen T, Borch-Johnsen K, Pedersen O . Studies of the synergistic effect of the Trp/Arg64 polymorphism of the beta3-adrenergic receptor gene and the -3826 A-->G variant of the uncoupling protein-1 gene on features of obesity and insulin resistance in a population-based sample of 379.... J Clin Endocrinol Metab. 2000; 85(9):3151-4. DOI: 10.1210/jcem.85.9.6790. View

12.

Nakano T, Shinka T, Sei M, Sato Y, Umeno M, Sakamoto K . A/G heterozygote of the A-3826G polymorphism in the UCP-1 gene has higher BMI than A/A and G/G homozygote in young Japanese males. J Med Invest. 2006; 53(3-4):218-22. DOI: 10.2152/jmi.53.218. View

13.

Willner I, Waters B, Patil S, Reuben A, Morelli J, Riely C . Ninety patients with nonalcoholic steatohepatitis: insulin resistance, familial tendency, and severity of disease. Am J Gastroenterol. 2001; 96(10):2957-61. DOI: 10.1111/j.1572-0241.2001.04667.x. View

14.

Angulo P . Nonalcoholic fatty liver disease. N Engl J Med. 2002; 346(16):1221-31. DOI: 10.1056/NEJMra011775. View

15.

Heilbronn L, Kind K, Pancewicz E, Morris A, Noakes M, Clifton P . Association of -3826 G variant in uncoupling protein-1 with increased BMI in overweight Australian women. Diabetologia. 2001; 43(2):242-4. DOI: 10.1007/s001250050036. View

16.

Osawa H, Mori Y . Sonographic diagnosis of fatty liver using a histogram technique that compares liver and renal cortical echo amplitudes. J Clin Ultrasound. 1996; 24(1):25-9. DOI: 10.1002/(SICI)1097-0096(199601)24:1<25::AID-JCU4>3.0.CO;2-N. View

17.

Baranova A, Gowder S, Schlauch K, Elariny H, Collantes R, Afendy A . Gene expression of leptin, resistin, and adiponectin in the white adipose tissue of obese patients with non-alcoholic fatty liver disease and insulin resistance. Obes Surg. 2006; 16(9):1118-25. DOI: 10.1381/096089206778392149. View

18.

Aygun C, Senturk O, Hulagu S, Uraz S, Celebi A, Konduk T . Serum levels of hepatoprotective peptide adiponectin in non-alcoholic fatty liver disease. Eur J Gastroenterol Hepatol. 2006; 18(2):175-80. DOI: 10.1097/00042737-200602000-00010. View

19.

Pagano C, Soardo G, Esposito W, Fallo F, Basan L, Donnini D . Plasma adiponectin is decreased in nonalcoholic fatty liver disease. Eur J Endocrinol. 2005; 152(1):113-8. DOI: 10.1530/eje.1.01821. View

20.

Colicchio P, Tarantino G, del Genio F, Sorrentino P, Saldalamacchia G, Finelli C . Non-alcoholic fatty liver disease in young adult severely obese non-diabetic patients in South Italy. Ann Nutr Metab. 2005; 49(5):289-95. DOI: 10.1159/000087295. View